AddLife (OM:ALIF B) Earnings Lift Puts Its Fair Value Narrative Back In Focus
Key points from AddLife’s latest earnings release
AddLife (OM:ALIF B) recently reported second quarter 2026 results that included SEK 2,721 million in sales and net income of SEK 130 million, alongside updated figures for the first half of the year.
For the six month period to June 30, 2026, AddLife reported sales of SEK 5,366 million and net income of SEK 257 million. Basic earnings per share from continuing operations reached SEK 2.11 for the half year.
See our latest analysis for AddLife.
The latest earnings improvement sits against a mixed share price picture for AddLife, with a 1 month share price return down 5.6% but a 3 year total shareholder return of 83.5%, indicating longer term investors have still seen strong gains despite a 1 year total shareholder return that has declined 8.0%.
If AddLife’s move has you thinking about where else capital might work hard in healthcare, it could be worth scanning other medical technology and diagnostics players through our 128 healthcare AI stocks.
After AddLife’s earnings lift but recent share price softness, the key decision now is straightforward: buy at today’s level, or wait and hope for a cheaper entry? And what does the valuation actually say about that trade off?
Most Popular Narrative: 17.1% Undervalued
On the latest numbers, the most followed narrative sees fair value for AddLife at SEK 190 per share, compared with the recent close of SEK 157.5. This frames the current debate around upside versus execution risk.
AddLife is prioritizing organic growth and profitability improvements through initiatives such as optimizing their product portfolio by removing less profitable products, which is expected to enhance gross margins and overall earnings. The company plans to leverage its strengthened balance sheet to accelerate acquisition activity, particularly in high-margin and fast-growing segments like orthopedic surgery, which could drive future revenue growth and increase EBITA margins.
Curious what kind of revenue expansion, profit margin lift, and future earnings multiple are baked into that SEK 190 fair value? The narrative leans heavily on earnings compounding and a richer P/E than the broader life sciences group, all anchored by a specific discount rate and detailed 3 year forecasts that investors may want to stress test themselves.
Result: Fair Value of SEK 190 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, AddLife’s thesis still relies on academic research funding holding up, and on supply chain or inventory swings not putting unexpected pressure on margins or cash flow.
Find out about the key risks to this AddLife narrative.
Another view on AddLife’s valuation
The first narrative for AddLife leans on fair value at SEK 190 per share, but the market is also looking at what investors are actually paying today. On a P/E of 32.1x, the stock sits below the Global Life Sciences average of 36.6x and in line with its fair ratio of 32.1x, which implies the market already prices in much of the current growth story.
If you want to see how that current P/E compares across peers and how much room there might be for sentiment to shift, take a closer look at the valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
If this mix of encouragement and caution around AddLife resonates, consider reviewing the data, weighing the trade offs and seeing the full picture with 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond AddLife?
If AddLife has sharpened your focus on quality, do not stop here. Broader opportunities across the market could matter just as much to your long term results.
- Target potential mispricings by scanning companies that combine quality fundamentals with low valuations through the 247 high quality undervalued stocks.
- Strengthen your income approach by reviewing stocks with higher yields that may offer more resilient payouts via the 458 dividend fortresses.
- Prioritize resilience by checking companies that pair solid balance sheets with robust fundamentals using the solid balance sheet and fundamentals stocks screener (419 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com